Anixa Biosciences (NASDAQ:ANIX) & Alvotech (NASDAQ:ALVO) Head-To-Head Survey

Alvotech (NASDAQ:ALVO) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Institutional and Insider Ownership

29.1% of Anixa Biosciences shares are held by institutional investors. 0.5% of Alvotech shares are held by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Alvotech and Anixa Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alvotech	-36.31%	N/A	-11.73%
Anixa Biosciences	N/A	-76.59%	-67.80%

Valuation and Earnings

This table compares Alvotech and Anixa Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90 million	2.38	$27.92 million	($0.61)	-7.62
Anixa Biosciences	$210,000.00	516.43	-$10.93 million	($0.32)	-9.75

Alvotech has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Alvotech has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Alvotech and Anixa Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2	1	4	0	2.29
Anixa Biosciences	1	1	3	0	2.40

Alvotech currently has a consensus price target of $8.50, indicating a potential upside of 82.80%. Anixa Biosciences has a consensus price target of $8.00, indicating a potential upside of 156.41%. Given Anixa Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Anixa Biosciences is more favorable than Alvotech.

Summary

Anixa Biosciences beats Alvotech on 8 of the 14 factors compared between the two stocks.

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

About Anixa Biosciences

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.